30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Year in Review

More 2010 Results: Exactech

EXACTECH
$190.5MM, +8% (U.S. $132MM, +8%; ex-U.S. $58.5MM, +7%)
* Hips, $28.7MM, +7%
* Knees $76.5MM, +1%
* Biologic & Spine $28MM, +2%
* Extremity $30MM, +32%
* Other $27.2MM, +12%

4Q10 revenue:
$51.8MM, +7% (U.S. $34.5MM, +8%; ex-U.S. $17.3MM, +7%)
* Hips, $8.2MM, +21%
* Knees $20.6MM, -2%
* Biologic & Spine $7.4MM, +7%
* Extremity $8.6MM, +32%
* Other $7MM, flat

* Extremities pricing stable during 2010
* New products supported 32% Equinoxe growth
* Extraordinarily good response to Optetrak PS Logic Knee
* Biologics segment soft; some competitive pressure from stem cell allografts
* Introduced proximal tibial spacer and FIT tray
* Launched BIOLOX delta ceramic femoral head, to use with existing Connexion GXL crosslinked poly liners
* Shoulder line extensions in varying stages of introduction, including Reverse Fracture Stem, Proximal Humerus Fracture Plate, anterior Augment Glenoid, Cage Glenoid Shoulders at ~10% of U.S. market share
* Investing in U.S. and ex-U.S. sales channels, continuing to build direct operations in Germany and Spain
* Ex-U.S., 50-55% of business direct vs. stocking
* 257 agents/reps in 2010, productivity per rep is increasing